ArticleOpen research Europe2025
Stakeholders' perceptions of the synergy between intellectual property and open science: A cross-sectional survey.
Article in Open research Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations in reagent manufacturing to support the global diagnostics supply chain.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The potential for intellectual property (IP) and open science (OS) to be used together for knowledge valorisation is increasingly discussed within research policy, yet their practical alignment remains limited. While researchers and research managers often regard IP and OS as potentially complementary, uncertainty persists about how to integrate them effectively in real-world contexts. Methods: To explore current perceptions and practices, a cross-sectional online survey was conducted, yielding 177 valid responses from individuals involved in research and research management across a range of research-performing organisations, primarily within Europe. Results: Although respondents were generally optimistic about the possibility of combining IP and OS, concrete examples of successful synergy remain rare. A lack of clear institutional guidance, limited awareness of open licensing mechanisms, and uncertainty about concurrent implementation were identified as key barriers. In collaborative projects, especially those involving multiple partners, differing objectives further complicate efforts to coordinate IP and OS strategies. National differences in legal frameworks across EU member states were also seen as an obstacle to synergy. The roles of knowledge transfer offices and OS ambassadors were highlighted as particularly important for supporting researchers in navigating complex decisions about licensing and compliance. However, sustained engagement with these actors remains inconsistent. Conclusions: To enable greater complementarity between IP and OS, early agreement on approaches within project management is essential. Researchers would benefit from targeted training to enhance understanding of open licensing tools and practical considerations. In addition, policy measures such as recognising OS contributions in academic career evaluation and introducing grace periods for patent filing could provide valuable support. These steps may assist institutions in managing the balance between openness and protection more effectively, encouraging broader and more confident application of both frameworks in practice. The study's findings should be interpreted with caution due to the small, purposive sample and potential response bias, which may limit generalisability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.